Filing Flows › Integrated Biopharma (INBP) › Q4 FY26
Integrated Biopharma (INBP) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Sep 25, 2026
Integrated Biopharma (INBP) reported revenue of $9.8M for the fourth quarter fiscal 2026 (Q4 FY26), -31% from a year earlier and -3% from the quarter before. Operating margin was -8.9%, net loss $1.4M (13.9% of revenue).
Integrated Biopharma, Q4 FY26: revenue $9.8M (-31% year over year), operating margin -8.9%, net loss $1.4M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.8M | -3% | -31% |
| Operating profit | −$869K | — | -248% |
| Net earnings | −$1.4M | — | — |
| Operating cash flow | −$1.2M | -331% | -302% |
What changed
Revenue was $9.8M in Q4 FY26, down 31% year over year and down 3% from the previous quarter. Contract Manufacturing was the largest line at 97% of revenue.
Gross margin was 0.3%, down 10.1 points from Q4 FY25. Operating costs exceeded revenue by $869K, an operating margin of -8.9%. Operating expenses grew 2% against a revenue fall of 31%. The quarter ended with a net loss of $1.4M, wider than the previous quarter's $837K loss.
Operating cash flow was −$1.2M. Non-cash charges added back $70K of depreciation and $51K of share-based compensation. Capital expenditures of $149K exceeded it, leaving free cash flow of −$1.3M.
Questions
What was Integrated Biopharma's revenue in the fourth quarter fiscal 2026?
Integrated Biopharma (INBP) reported revenue of $9.8M for the fourth quarter fiscal 2026 (Q4 FY26), -31% from a year earlier and -3% from the quarter before.
Was Integrated Biopharma profitable in the fourth quarter fiscal 2026?
Operating loss was $869K (-8.9% of revenue) and net loss $1.4M.